Akash Maniam, MD MBA’s Post

The American Society of Clinical Oncology (ASCO) 2024 presentation showcased Cue Biopharma's Phase I trial of its leading interleukin 2 (IL-2)-based biologic, CUE-102, targeting Wilms’ Tumor 1 positive recurrent or metastatic cancers. CUE-102 has the potential to significantly alter the treatment landscape for patients with WT1-positive cancers by offering higher efficacy and lower toxicity compared to currently available treatments. Experience Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's Special ASCO 2024 Coverage! https://lnkd.in/gs_rdz_j #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

I had the pleasure of reading some recent ASAP articles for ACS Med Chem Lett. They are super quick reads and cover a broad range of interesting topics. I wrote the recent "In This Issue" on 3 of my favorites:

New paper out: "Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC". In this review, we remark the recent efforts to develop new reversible next-generation Tyrosine Kinase Inhibitors of Epidermal Growth Factor Receptor to fight the resistance against T790M and C797S mutations. We report an overview of the role of the EGFR’s signaling pathways in cancer progression and the most relevant approved drugs and drug candidates, which are discussed in terms of chemical structure and binding modes, providing important guidelines for the discovery and the development of new drugs. https://lnkd.in/ddHphBmn

We are thrilled to share a recording of a GlycoNet webinar featuring Dr. Paula Videira, Co-Founder of CellmAbs, Co-director of GLYCOTwinning, and Associate Professor at Faculdade de Ciências e Tecnologia da Universidade NOVA de Lisboa. Introduced by Mr. David Firer, Chair of the GlycoNet Trainee Association – Executive Committee, Dr. Videira dives deep into "Unlocking the Glycoimmune Potential: Novel Strategies for Advanced Immunotherapy". Additionally, don’t miss the insightful presentation by her PhD student, Ms. Rita Adubeiro Lourenço, on "Deciphering the Enigmatic Role of O-glycan Signatures in Cancer". 👉 Watch the full recording here: https://lnkd.in/drFNUuS2 Learn more about GlycoNet and GLYCOTwinning and join us in advancing the field of glycomics and immunotherapy. #GlycoNet #GLYCOTwinning #Glycomics #glycobiology #CancerResearch #Glycoscience #Webinar

Excited to announce that our latest publication is available now! We have employed a combination of spectroscopic and biochemical techniques to delve into the spectral characterization of heme-binding sites and monitor dimerization pathways. If you are curious about the applications of CD spectroscopy, Size exclusion chromatography, protein purification, or the intricacies of dimerization routes, this publication is a must-read! #BioinorganicChemistry #Biochemistry #Spectroscopy #CircularDichroism #DensityFunctionalTheory #HemeProtein #SizeExclusionChromatography #ResearchPublication #ProteinCharacterization #DimerizationPathways #ScienceCommunity #ACSBiochemistry

New in #chronicmyeloidleukemia management on #Heme Today: A phase II trial led by Elias Jabbour, MD, of MD Anderson Cancer Center found #dasatinib plus #venetoclax to be effective and safe for chronic phase #CML https://lnkd.in/eKPiSkq3

In a recent study published in the journal Biochemistry, Prajakta Badve and Katlyn Meier exploited a combination of several spectroscopic techniques and computational modeling to explore the binding of the progesterone receptor membrane component 1 (PCRMC1) to heme. From this study, key information on this binding event and subsequent PGRMC1 dimerization were identified, which could have signifiant implications on chemotherapies employed for cancer treatment. Check out the work at the link below: https://lnkd.in/eX5B8BeS

In a phase II trial led by Elias Jabbour, MD, of MD Anderson Cancer Center, #dasatinib plus #venetoclax was effective and safe for pts with chronic phase #chronicmyeloidleukemia #CML, #Heme https://lnkd.in/eKPiSkq3

ICYMI in #chronicmyeloidleukemia management on #Heme Today: In a phase II trial led by Elias Jabbour, MD, of MD Anderson Cancer Center, #dasatinib plus #venetoclax demonstrated efficacy and was safe for chronic phase #CML  https://lnkd.in/eKPiSkq3

Quite an interesting article about ADCs and PDCs. No idea what these acronyms mean? This article is quite educational as well. Even if you are not a medicinal chemist but are interested in modern technologies and how scientists try to make chemotherapies more targeted to avoid side effects, it's definitely worth reading. Great work, Yu Cheng, Xifu Liu, and Ling Zhang et al. https://lnkd.in/dBUXfUZ4